Gilead comes around on Truvada PrEP marketing, opening up a new world of HIV sales

Gilead is now marketing HIV med Truvada as a preventative for healthy people.

Gilead's had an FDA go-ahead since 2012 to market HIV med Truvada as a preventative med for healthy people. But the company has only just started to market it that way.

Promotional activities around Truvada for pre-exposure prophylaxis, or PrEP, kicked off in July, when Gilead began marketing its med to doctors through professional publications and digital advertising, among other channels, Reuters reports.

And this fall, the Big Biotech took its message straight to consumers with print advertisements in publications aimed at the LGBTQ community, such as OUT, Advocate and SWERV. Next up? Social media and digital marketing, the company says.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

It’s a change of course for Gilead, which has taken heat for failing to pump its own dollars into spreading the PrEP message. The company initially yielded to patient advocate concerns that promoting the med as a preventative could encourage promiscuity and unsafe practices.

Activists, though, railed at the California drugmaker for staying mum; thanks to that decision, doctors also didn’t know about PrEP or about Gilead’s patient assistance program, which helps most users sink monthly costs for the pricey drug to about $25.

The "criticism now is we're not saying enough," David Piontkowsky, Gilead's vice president of HIV Medical Affairs, told the news service.

Meanwhile, Truvada for PrEP has begun to catch on even without Gilead’s commercial support.  As many as 90,000 people in the U.S used the product for prevention in Q3, Reuters notes, up from 60,000 to 70,000 earlier this year. Those figures were helped by a 2014 CDC recommendation that Americans at high risk of infection—including men who have sex with men, transgender women who have sex with men, partners of people who are HIV-positive and intravenous drug users who share needles—take the pill as a preventative measure.

And 90,000 is just tip of the iceberg, according to the CDC's estimates. In 2015, the body pegged the number of Americans at substantial risk of HIV infection at about 1.2 million.

Gilead certainly wouldn’t mind seeing sales of Truvada—which totaled $1.8 billion through the first 9 months of this year—expand, especially considering the hep C slowdown that’s been whacking the company’s top line. Revolutionary meds Sovaldi and Harvoni, which broke launch records on their way to blockbuster sales, have stumbled on competition and payer discounting, with hep C sales tanking by 31% in the third quarter.


Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.